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Background: Percutaneous treatment of coronary bifurcation lesions remains
hampered by suboptimal results, mainly in the side branch (SB), even with the use of
drug-eluting stents (DES). Drug-eluting balloons (DEB) could provide an attractive
alternative to treat bifurcations in combination with a provisional T-stenting technique
in order to minimize SB restenosis. We compared angiographic and clinical outcomes
of a provisional T-stenting technique with the first generation DIOR DEB plus bare
metal stent (BMS) versus BMS versus paclitaxel DES.
Methods: In this randomized, international multicenter, single-blinded 3-arm study,
117 patients with coronary bifurcation lesions underwent treatment with: A) DEB in
both main branch (MB) and SB and BMS in MB; B) BMS in MB and regular balloon
angioplasty in SB; or C) paclitaxel DES in MB and regular balloon in SB. All patients
underwent provisional T-stenting with an identical stent platform in the MB. Paclitaxel
was the drug for elution in groups A and C. This abstract presents the 18-month major
adverse cardiac events (MACE: death, myocardial infarction, target vessel
revascularization (TLR)) and 6-month angiographic results.
Results: In-hospital 8 MACE were reported, all were peri-procedural myocardial
infarctions (MI); 3 (7.5%), 2 (5.4%), and 3 (7.5%) in groups A, B, and C respectively.
Between discharge and 18-month follow-up results were: 1 (2.5%) cardiac death in
group A due to a nontarget vessel related MI. Furthermore, 1 (2.5%) MI due to a stent
thrombosis with consecutively a TLR was reported in group C. Total TLR rate at 18-
month was 8 (20%), 10 (27%), and 6 (15%) in groups A, B, and C respectively. The
cumulative MACE rate at 18-month was 22.5%, 29.7%, and 17.5% (p=0.47), and the
6-month angiographic binary restenosis rates per bifurcation were 24.2%, 28.6%, and
15% in groups A, B, and C respectively.
Conclusion: Pre-treatment of both MB and SB with the first generation DIOR DEB
failed to show 6-month angiographic and 18-month clinical superiority over BMS.
Moreover DES showed superior angiographic results than DEB and BMS.
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Background: The aim of the present study was to evaluate the temporal arterial
distribution of a novel nano particle sirolimus (nSRL) delivered locally using an
angioplasty balloon catheter in a rabbit ilio-femoral artery model.
Methods: The fluorescent dye 5-DTAF (Molecular Probes) was used to label nSRL
where 180 μg of drug was then spray-coated onto 3 x 15 mm balloon catheters (Magic
Touch, Concept Medical Inc., Twinsburg, OH). Bilateral ilio-femoral rabbit arteries
pre-injured with a 3F Fogarty catheter were treated with nSRL by 60 seconds inflation
of the balloon catheter at nominal pressure and harvested at 1, 24 hours and 3, 7 days
and assessed using laser confocal scanning microscopy.
Results: Confocal examination showed DTAF-nSRL as a solid to diffuse bright green
signal admixed with dark non-fluorescent areas (Fig. 1A). For arteries examined en
face, DTAF-signal was viewed as solid to more diffuse weaker fluorescence not to
exceed an estimated 25% to 35% of the luminal surface at 1 and 24-hours. At 3- and
7-days, the distribution of signal was markedly less. Histologic cross-sections examined
at 1 hr post-treatment showed a strong accumulation of DTAF-nSRL localized to the
IEL surface not exceeding 70% of the vessel circumference (Fig. 1B). By 24 and 72
hours however, the DTAF label was observed as a strong to faint punctate fluorescence
associated with the IEL and upper medial layer (Fig. 1C). At 7-days, the pattern of
DTAF was identified as a moderate to weak punctate fluorescence widely distributed
throughout the medial wall with rare particulate in the adventitia.
Figure 1. Representative confocal images.
Conclusion: The present study for the first time provides a visual assessment of the
distribution of a novel nano carrier sirolimus when delivered locally to the arterial wall
in vivo using a balloon catheter.
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Background: Previous pathologic studies in 1st-generation drug-eluting stents (1st-
gen DES; sirolimus- [SES] and paclitaxel- [PES]) have demonstrated that delayed
arterial healing is accompanied by poor endothelialization as the primary substrate
underlying late stent thrombosis (LST). Several clinical studies have reported that 2nd-
generation everolimus-eluting stent (EES) shows a lower incidence of LST than 1st-gen
DES. Little is known about the pathologic findings of EES in human coronary arteries.
Methods: From our stent registry, a total of 111 autopsy cases to include 155 DES
lesions (1st-gen DES=136 [61 SES, 75 PES] and EES=19) with duration of implant
>30 days and ≤2 years were examined. Histomorphometry was performed on EES vs.
1st-gen DES where endothelial strut coverage, fibrin deposition, and inflammatory
response were assessed.
Results: Age, sex, risk factors, and duration of implant (1st-gen DES=211 [91-383]
vs. EES=180 [151-360] days, p=0.64) were similar between 2 groups. LST was more
frequent in 1st-gen DES than in EES (25.7% vs. 5.3%, p=0.04). Only 1 lesion with
LST in EES was a device implanted over an underlying PES. The results of
histomorphometry are shown in Table. The percent of uncovered struts was
significantly lower in EES, while mean neointimal thickness did not differ between
the groups. Moreover, inflammation and fibrin deposition were significantly less in
EES as compared to 1st-gen DES.
Conclusion: EES shows a lower incidence of LST and substantially less uncovered
struts with similar neointimal thickness, less inflammation, and less fibrin deposition
as compared to 1st-gen DES in humans. These findings are consistent with greater
clinical safety of EES.
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Biodegradable Polymer-Coated Sirolimus-Eluting Stent Implantation in Acute
Myocardial Infarction
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Background: The present study sought to evaluate the safety and effectiveness of
Excel in acute myocardial infarction with 6-month dual antiplatelet therapy in daily
practice.
Methods: Since November 10, 2006, a policy of routine Excel stents implantation has
been instituted in 59 centers from 4 countries. During 6 months of enrollment, 760
patients with acute myocardial infarction underwent percutaneous recanalization and
Excel stents implantation. Six-month angiographic follow-up was scheduled per
protocol.
www.JACC.TCTAbstracts2011






TUESDAY, NOVEMBER 8, 2011, 10:15 AM - 12:25 PM
Results: Overall, 1082 target lesions were identified. The target lesions were A type
in 111 cases (10.3%), B1 in 201 (18.6%), B2 in 252 (23.3%), and C in 518 (47.9%).
Complete follow-up was available for 99.3% of the patients at 180 days, 99.1% at 360
days, and 99.1% at 540 days. A total of 17 deaths occurred during the 180 days (2.3%),
25 deaths occurred during the 360 days, and 27 deaths occurred during the 540 days.
In none of these cases, death occurred as an unexpected, sudden episode that could be
attributable to stent thrombosis. no patient had recurrent myocardial infarction, and
there were no additional reinterventions. Also, 5 thrombosis events by ARC definition
at 18-months were documented. The average duration of clopidogrel treatment was
180 days. The cumulative rates of major adverse cardiac events were 2.0% at 180 days,
3.9% at 1 year, and 4.2% at 18 months. Overall rate of stent thrombosis was 0.87% at
18 months. The rates of acute, subacute, late, and very late stent thrombosis were 0.1%,
0.38%, 0.34%, and 0.05%, respectively. Angiographic follow-up, performed in 974
(31.6%) lesions from 653 patients (31.7%), revealed a mean in-stent late lumen loss
of 0.21 ± 0.39 mm. Binary restenosis rates were 3.8% in-stent and 6.7% in-segment.
Conclusion: This multicenter registry documents satisfactory safety and efficacy
profiles, as evidenced by low rates of major adverse cardiac events and stent thrombosis
up to 18 months, for the Excel biodegradable polymer-based sirolimus-eluting stent.
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Background: Multislice computed tomography (MSCT) coronary angiography has
emerged as a non-invasive diagnostic modality to evaluate coronary artery disease.
However, visualization or evaluation of the in-stent lumen by MSCT is challenging
owing to the blooming artefact caused by metallic stent struts. The feasibility and
accuracy of the use of MSCT in the analysis of radiolucent bioresorbable scaffolds
could indicate a new era for non-invasive assessment of patients treated with
radiolucent devices.
Methods: The ABSORB Cohort B trial enrolled 101 patients at 12 sites in the
European and Asia Pacific regions between March and November 2009. The current
aim is to assess, by MSCT, the midterm results at 18 months in terms of patency and
absence of binary restenosis of the ABSORB bioresorbable everolimus eluting vascular
scaffold (Abbott Vascular, Santa Clara, CA, USA).
Results: In the smaller ABSORB Cohort A study, we have previously demonstrated
that non-invasive imaging of the ABSORB scaffold patency with MSCT is feasible
without the artifacts associated with conventional metal stents. In the ABSORB Cohort
B trial, clinical data up to 1 year for the full cohort of 101 patients are currently
available. In these 101 patients, 1 year results showed an ID-MACE rate of 6.9%. The
18-month clinical and MSCT results for the full cohort of 101 patients from the
ABSORB Cohort B trial will be presented.
Conclusion: Eighteen month data are currently being collected and we will present
18-month clinical and MSCT results for the full cohort of patients from the ABSORB
Cohort B trial.
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Background: Very small coronary vessels (reference diameter <2.5mm) are often
associated with diabetic and female patients and remain an important challenge in
interventional cardiology. We studied a large population of patients with very small
vessels treated with Nobori DES coated only abluminally with a matrix of biolimus
A9 and a biodegradable polymer.
Methods: We studied 1284 patients with at least one lesion located in a very small
vessel (SV) treated with Nobori stent. The primary endpoint of the study is target lesion
failure (TLF) defined as cardiac death, target vessel related myocardial infarction (MI)
and target lesion revascularization (TLR). Data are captured electronically with an
extensive monitoring (100% on-line and 30% on-site). An independent clinical event
committee adjudicated all adverse events and an independent corelab analyzes baseline
and adverse events angiograms.
Results: Patients were 65±11 years old, 23% were female, 34.8% had undergone
previous PCI treatment, 52.1% were admitted with acute coronary syndrome, 32.6%
were diabetic (7.6% insulin dependent) and more than 70% were hyperlipidemic and
hypertensive. A mean number of 1.96±1.18 stents were implanted per patient, with
1.67±0.86 lesions per patient treated. Direct stenting was performed in 27.7% of the
procedures and femoral access site was used in 61% of the patients. A total of 69% of
the lesions were complex (type B2+C), 26.4% calcified, 20.0% bifurcated, 10.6% ostial
and 6.3% presented ulceration. By QCA the mean RVD was 2.29±0.48mm. At 2 years,
94.7% of the patients were available for follow-up with reported TLF rate of 3.7% and
stent thrombosis rate of 0.8%.
Conclusion: Although very small vessels are considered challenging to treat and
represent a higher risk for adverse outcomes, this analysis showed very low rates of
TLF and stent thrombosis up to 2 years, indicating excellent efficacy and safety of the
Nobori stent in the treatment of very small vessels.
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Background: The second generation Bioresorbable Everolimus Eluting Vascular
Scaffolds (BVS) are untested at the mid-term follow-up in the subset of small coronary
vessels. We investigated the performance of the second generation BVS (Abbott
Vascular, Santa Clara, CA) in small coronary arteries (<2.5mm) at 1-year follow-up
Methods: The ABSORB Cohort B Trial is a multicentre single-arm, prospective, open-
label trial enrolling 101 patients. In the present post-hoc analysis, the study population
was sorted according to the pre-procedural reference vessel diameter (RVD) into two
groups: 1) Small-vessel group with RVD <2.5mm (41 patients, 41 lesions) and 2)
Large-vessel group with RVD >=2.5 mm (60 patients, 61 lesions). Clinical outcomes
were assessed at one-year follow-up for the entire population and compared between
the two groups. Out of the total population 45 patients were assigned to undergo 6-
month coronary angiography and 56 patients (57 lesions) to have the procedure
performed at one year.
Results: At one-year after implantation no differences in Ischemia-Driven (ID) Major
Adverse Cardiovascular Events (small vessels 3/41 cases, 7.3% vs. large vessels 4/60
cases, 6.7%,p=1.0000), Myocardial Infarction (small vessels 2/41 cases, 4.9% vs large
vessels 1/60 case, 1.7%,p=0.5645) and ID-Target Lesion Revascularization (small
vessels 1/41 case, 2.4% vs large vessels 3/60 cases, 5.0%, p=0.6445) were reported
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